Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 29, 2021

Cynata to expand recruitment criteria in Covid-19 treatment trial 

Cynata Therapeutics is all set to expand recruitment criteria in its active MEseNchymal coviD-19 (MEND) clinical trial of Cymerus mesenchymal stem cells (MSCs) in intensive care patients with respiratory failure.

Cynata Therapeutics is all set to expand recruitment criteria in its active MEseNchymal coviD-19 (MEND) clinical trial of Cymerus mesenchymal stem cells (MSCs) in intensive care patients with respiratory failure.

The latest development comes after the company received ethics committee approval for the expansion.

In the initial stage, the trial was designed to assess the early efficacy of Cymerus MSCs in Covid-19 patients admitted to intensive care.

The open-label, randomised, controlled trial will now analyse the early efficacy of Cymerus MSCs in patients with respiratory failure.

It can now enrol patients with respiratory failure arising from other causes, such as influenza, with Covid-19 no longer a requirement.

This move could help expand the pool of potential participants for the trial, considering the present state of control of the Covid-19 in Australia.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Cynata plans to have 24 adult intensive care patients with respiratory distress or compromised lung function at certain hospitals in the country.

Cynata chief operating officer Dr Kilian Kelly said: “This expansion will increase the number of patients eligible for recruitment into this trial, which is designed to investigate the potential benefits of our MSCs in treating these severely ill patients.”

In a separate development, the National Institute for Health Research (NIHR) in the UK has granted Urgent Public Health (UPH) prioritisation to UNION therapeutics’ PROTECT-V trial of UNI91103, a niclosamide-based nasal spray for Covid-19 in kidney patients.

The treatment candidate, which is being developed for prophylaxis and treatment of Covid-19, can potentially inhibit SARS-CoV-2. Niclosamide has shown to avert fatal outcomes in a murine challenge model of Covid-19 when administered intranasally.

With this development, the trial will now get infrastructure support which will aid in the accelerated recruitment of patients in the study.

UNION co-founder professor Morten Sommer said: “We are pleased that our Covid-19 programme has achieved this important recognition through the UPH prioritisation of the PROTECT-V study as it paves the way for a faster and more efficient conduct of the trial.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU